Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial [0.03%]
安罗替尼联合TQB2450（抗PD-L1抗体）治疗晚期肺腺泡状软组织肉瘤患者：一项单臂Ⅱ期临床试验
Zhichao Tan,Yan Wu,Zhengfu Fan et al.
Zhichao Tan et al.
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft-tissue sarcoma with a high rate of metastasis and no established treatment. This study aimed to explore the efficacy and safety of anlotinib (a tyrosine kina...
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY) [0.03%]
帕博利珠单抗联合拉姆西芦马布新辅助治疗PD-L1阳性NSCLC的疗效、安全性和对肿瘤微环境的影响：一项II期研究（EAST ENERGY）
Keiju Aokage,Shohei Koyama,Shogo Kumagai et al.
Keiju Aokage et al.
Purpose: Angiogenesis inhibitors are known to modify tumor immunity. Combination of angiogenesis inhibitors with immune checkpoint inhibitors has shown efficacy against many types of cancers, including non-small cell lung...
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study [0.03%]
用于类癌患者的监测生物标记的循环中黑色素细胞瘤相关蛋白——CASPAR研究
Qing H Meng,Thorvardur R Halfdanarson,Joshua A Bornhorst et al.
Qing H Meng et al.
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are relatively indolent but can be more aggressive. The current recommendations for using serum chromogranin A (CgA) for patients with GEP-NET are equivocal....
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors [0.03%]
一项评估ATR抑制剂Berzosertib单药治疗四种分子定义的晚期实体瘤队列的转化研究
Gregory M Cote,Bose S Kochupurakkal,Khanh Do et al.
Gregory M Cote et al.
Background: Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors car...
Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer [0.03%]
遗传系别DNA损伤修复变异体与高危或转移性前列腺癌患者的预后关系
Konrad H Stopsack,Joseph Vijai,Michael Conry et al.
Konrad H Stopsack et al.
Purpose: Deleterious germline variants in certain DNA repair genes are risk factors for developing aggressive prostate cancer. The objective was to quantify their prognostic impact after prostate cancer diagnosis. ...
Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C [0.03%]
帕博西尼治疗CDK4/6扩增肿瘤的二期研究：NCI-MATCH ECOG-ACRIN试验（EAY131）Z1C子协议结果分析
Mark H O&#x;Hara,Opeyemi Jegede,Mark A Dickson et al.
Mark H O&#x;Hara et al.
Purpose: Amplification of CDK4 and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of the NCI-MATCH...
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates [0.03%]
代谢肿瘤体积作为预测生物标志物用于评估免疫检查点阻断剂在晚期非小细胞肺癌中的作用及其生物学相关性
Filippo G Dall&#x;Olio,Wael Zrafi,Veronique Roelants et al.
Filippo G Dall&#x;Olio et al.
Purpose: This study aimed to explore metabolic tumor volume (tMTV) as assessed 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT), and understand its biological meaning in patients wi...
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A [0.03%]
一种新型PDE3A-SLFN12复合物诱导剂BAY 2666605在晚期实体瘤患者中的首次人体剂量递增研究：SLFN12和PDE3A共表达人群
Kyriakos P Papadopoulos,Meredith McKean,Silvia Goldoni et al.
Kyriakos P Papadopoulos et al.
Purpose: The study aims to evaluate the safety, tolerability, and pharmacokinetics of BAY 2666605, a velcrin that induces complex formation between the phosphodiesterase PDE3A and the protein Schlafen 12 (SLFN12), leading...
Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy [0.03%]
基因组生物标志物预测ATR抑制和放疗联合治疗的反应
Benjamin R Schrank,Lauren E Colbert
Benjamin R Schrank
For decades, chemoradiosensitization with checkpoint kinase inhibitors has been proposed but largely unexplored. A recent study reports that the novel ataxia telangiectasia and Rad3-related kinase inhibitor RP-3500 synergizes with radiation...
Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer [0.03%]
化疗可激发转移性卵巢癌中的三级淋巴器官结构生成
Jesús Bravo Melgar,Damya Laoui
Jesús Bravo Melgar
Ovarian cancer remains resistant to immunotherapy in most patients, highlighting the need to make these tumors more immunogenic. A recent study unveils how chemotherapy is able to induce cancer cell stress in metastatic ovarian carcinomas, ...